SLC-391
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SLC-391, covering 2025-12-18 to 2025-12-18. Get the full timeline:
Most recent: Clinical Trial Update: Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers [Phase 1, Phase 2]